Bildnachweis: FGK Clinical Research.
FGK Clinical Research is strengthening its European footprint with an operational presence in the Netherlands. The Munich-headquartered contract research organisation (CRO) is expanding its operative team to support clinical studies for international clients and tap into the country’s growing biotechnology ecosystem.
The Netherlands has developed into a key European hub for biotech innovation, attracting significant investment and offering favourable conditions for clinical research. FGK aims to support both domestic and international biotech companies with local expertise in trial management, monitoring and regulatory affairs.
Martin Krauss, Managing Director of FGK Clinical Research GmbH, says:
„The decision to set up an operative team in the Netherlands is a natural progression of our sustained growth and our dedication to serving our clients where innovation thrives. The Dutch biotechnology landscape is incredibly promising, and we are eager to bring our extensive experience and full spectrum of clinical trial services directly to companies aiming for clinical studies in this region. Our local presence will facilitate closer collaboration, provide more tailored support, and ultimately accelerate the development of vital new therapies.“
International growth strategy
The expansion of the operative team into the Netherlands mirrors FGK’s successful organic expansion strategy which led to the establishment of several offices in Central Eastern Europe between 2006 and 2010 (Poland, Czech Republic, Hungary), the opening of a branch office in Berlin in 2020, the acquisition of Clinicology Ltd. in the UK in 2022 and the opening of a Boston office. Ursula Türcke, Senior Director Clinical Operations at FGK, adds:
„We understand the unique challenges and opportunities faced by biotechnology companies, particularly those focused on novel therapies. Our aim in the Netherlands is to become an indispensable partner, offering not just operational excellence but also strategic insights that help companies bring their innovations to patients faster and more effectively. We are excited to contribute to the continued growth and success of the Dutch biotech community.”
